Por favor, use este identificador para citar o enlazar este ítem:
|Título :||Pharmacist-Physician interprofessional collaboration to promote early detection of cognitive impairment : increasing diagnosis rate|
|Autor :||Ramos García, Hernán.|
Pardo Albiach, Juan.
Sánchez Roy, Rafael.
Pérez Tur, Jordi.
Navarro Clérigues, Andrés José.
Moreno Royo, Lucrecia.
|Materias:||Farmacias.; Drugstores.; Memory disorders.; Pharmaceutical services.; Memoria - Trastornos.; Atención farmacéutica.|
|Fecha de publicación :||1-abr-2021|
|Editorial :||Frontiers Media.|
|Citación :||Ramos, H., Pardo, J., Sánchez, R., Puchades, E., Pérez-Tur, J., Navarro, A. et al. (2021). Pharmacist-Physician interprofessional collaboration to promote early detection of cognitive impairment: increasing diagnosis rate. Frontiers in Pharmacology, vol. 12, art. 579489 (apr.). DOI: https://doi.org/10.3389/fphar.2021.579489|
|Resumen :||The increased pressure on primary care makes it important for other health care providers, such as community pharmacists, to collaborate with general practitioners in activities related to chronic disease care. Therefore, the objective of the present project was to develop a protocol of action that allows close pharmacist-physician collaboration to carry out a coordinated action for very early detection of cognitive impairment (CI). Methods: A comparative study to promote early detection of CI was conducted in 19 community pharmacies divided into two groups: one group with interprofessional collaboration (IPC) and one group without interprofessional collaboration (NonIPC). IPC was defined as an interactive procedure involving all pharmacists, general practitioners and neurologists. A total of 281 subjects with subjective memory complaints were recruited. Three tests were used in the community pharmacies to detect possible CI: Memory Impairment Screening, Short Portable Mental State Questionnaire, and Semantic Verbal Fluency. Individuals with at least one positive cognitive test compatible with CI, were referred to primary care, and when appropriate, to the neurology service. Finally, we evaluated the differences in clinical and diagnostic follow-up in both groups after six months. Results: The NonIPC study group included 38 subjects compatible with CI referred to primary care (27.54%). Ten were further referred to a neurology department (7.25%) and four of them (2.90%) obtained a confirmed clinical diagnosis of CI. In contrast, in the IPC group, 46 subjects (32.17%) showed results compatible with CI and were referred to primary care. Of these, 21 (14.68%) were subsequently referred to a neurology service, while the remaining 25 were followed up by primary care. Nineteen individuals out of those referred to a neurology service obtained a confirmed clinical diagnosis of CI (13.29%). The percentage of subjects in the NonIPC group referred to neurology and the percentage of subjects diagnosed with CI, was significantly lower in comparison to the IPC group (p-value 0.0233; p-value 0.0007, respectively). Conclusions: The creation of IPC teams involving community pharmacists, general practitioners, and neurologists allow for increased detection of patients with CI or undiagnosed dementia and facilitates their clinical follow-up. This opens the possibility of diagnosis in patients in the very early stages of dementia, which can have positive implications to improve the prognosis and delay the evolution of the disease.|
|Descripción :||Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.frontiersin.org/articles/10.3389/fphar.2021.579489/full|
Este artículo pertenece a la Cátedra DeCo MICOF-CEU UCH, Cátedra para el estudio del Deterioro Cognitivo.
|ISSN :||1663-9812 (Electrónico)|
|Aparece en las colecciones:||Dpto. Farmacia|
Ficheros en este ítem:
|Pharmacist_Ramos_FIP_2021.pdf||1,47 MB||Adobe PDF||Visualizar/Abrir|
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.